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Abstract
Background: Intravesical instillation of Bacillus Calmette-Guérin (BCG) is the treatment of choice for superficial
bladder carcinoma. Complications of BCG therapy include local infections and disseminated BCG infection with
multiple endorgan complications.
Case Presentation: We report a case of disseminated, post-treatment BCG infection that initially presented with
granulomatous hepatitis and choroiditis. After successful anti-mycobacterial therapy and resolution of the hepatic
and ocular abnormalities, the patient developed an acute upper gastrointestinal hemorrhage from an
aortoduodenal fistula that required emergency surgery. The resection specimen revealed multifocal, non-caseating
granulomas, indicating mycobacterial involvement.
Conclusions: This case highlights the varied end organ complications of disseminated BCG infection, and the need
for vigilance even in immuno-competent patients with a history of intravesical BCG treatment.
Background
Bacillus Calmette-Guérin (BCG) is a live, attenuated
strain of the bovine tuberculosis bacillus, Mycobacter-
ium bovis. Immunotherapy of neoplastic disease with
BCG was developed in the 1960s and has been used for
multiple neoplasms including malignant melanoma and
acute lymphoblastic leukemia. In 1976, Morales et al.
were the first to use intravesical BCG instillation to
treat superficial bladder cancer [1]. Since then, BCG
therapy has become the treatment of choice for early
stage transitional cell carcinoma of the bladder, with
response rates ranging from 60%-94% - higher than any
chemotherapeutic agent [2].
Although the virulence of attenuated BCG is low, ser-
ious and potentially life-threatening infections can occur
even in the immunocompetent host. Adverse effects of
BCG immunotherapy develop in 3-5% of patients [3].
They include local complications such as bacterial cysti-
tis, bladder contractures, granulomatous prostatitis,
epididymitis, orchitis, and systemic reactions such as
fever, malaise, hepatitis, and pneumonitis. Disseminated
BCG infections presenting as pneumonitis or granulo-
matous hepatitis, are rare: in the largest retrospective
study reported to date, dissemination occurred in 0.7%
of over 2,000 patients [4]. Ocular BCG manifestations
include uveitis, endophthalmitis, and rarely choroiditis
[5,6]. The mechanism of BCG-related choroiditis is
unclear - it may be due to a hypersensitivity response or
to direct choroidal seeding by the bacteria. Vascular
complications of BCG infection are well-known, and
include infection and primary aortoenteric fistualization
[7,8].
We present a case of Mycobacterium bovis hepatitis
and choroiditis occurring in an immunocompetent host
more than one year after intravesical BCG treatment for
bladder cancer. Following prolonged antimycobacterial
therapy, the patient developed an aortoduodenal fistula
that required emergency surgery and prompted a repeat
course of antibiotics. To our knowledge, this constella-
tion of end-organ complications of systemic, BCG infec-
tion has not previously been reported.
* Correspondence: cfimmel@lumc.edu
1Division of Gastroenterology, Hepatology and Nutrition, Loyola University
Medical Center, 2160 South 1st Avenue, Maywood, IL 60153, USA
Full list of author information is available at the end of the article
Gao et al. BMC Infectious Diseases 2011, 11:260
http://www.biomedcentral.com/1471-2334/11/260
© 2011 Gao et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Case Presentation
A 61-year-old patient presented to the Hepatology clinic
in September of 2008 with a six-month history of ele-
vated alkaline phosphatase levels. He gave a history of
malaise, low-grade fever, night sweats and a 50 lbs weight
loss (Figure 1). His prior workup included laboratory,
radiologic and endoscopic tests, including ultrasound,
esophago-gastro-duodenoscopy (EGD) and endoscopic
retrograde choledochopancreatography (ERCP), all of
which were unrevealing. Serological tests for viral or
autoimmune hepatitis, primary biliary cirrhosis, and
other concomitant liver diseases were negative.
The patient had no history of immunodeficiencies. He
had been diagnosed with superficial transitional cell car-
cinoma (TCC) of the bladder (Stage T1 with invasion
into the lamina propria) in 2007. His initial treatment
consisted of cystoscopic fulguration of the tumor. How-
ever, follow-up examinations revealed a local recurrence.
Intravesical immunotherapy with weekly instillations of
BCG (150 mg lyophilized Pasteur strain) was adminis-
tered for a total of 6 weeks, starting in May, 2007. No
immediate complications or traumatic instillations were
reported.
On further laboratory testing, the patient’sa l k a l i n e
phosphatase level rose to and peaked at 1100 IU/L (Fig-
ure 1). This was associated with mild increase in transa-
minases (AST 56 IU/L, ALT 60 IU/L). On physical
exam, the patient was anicteric. Tender hepatomegaly
was present. Aerobic and anaerobic bacterial blood cul-
tures were negative, as was a PCR serum assay for cyto-
megalovirus. The patient was admitted to the hospital
for further workup.
Computed tomography of the chest, abdomen and
pelvis was performed to exclude recurrent transitional
cell cancer and other malignancies. The lung images
revealed multiple small nodules distributed randomly
throughout both lungs, suggestive of an infiltrative, pos-
sible infectious process. Given the history of prior BCG
treatment, the possibility of pulmonary or disseminated
mycobacterial infection was raised. A liver biopsy was
performed because of the marked liver enzyme eleva-
tions, and showed multiple, non-caseating granulomas
with Langerhans giant cells (Figure 2); Ziehl-Neelson
staining of the liver tissues fora c i d - f a s tb a c i l l i( A F B ) ,
and Gomori’s methamine silver (GMS) staining for fun-
gal organisms with appropriate controls were negative.
Because of the continued concern over mycobacterial
infection, bone marrow and repeat liver biopsies with
mycobacterial culture were performed one month later.
Noncaseating granulomas were present on both liver
and bone marrow biopsies (Figure 2 and 3). AFB stains
were again negative, but mycobacterial cultures were
positive in both cases. Mycobacterial isolates from both
sources were sensitive to streptomycin, isoniazid, rifam-
pin, and ethambutol. PCR analysis of liver tissue con-
firmed the presence of Mycobacterium bovis BCG DNA,
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resistance to pyrazinamide.
During this stage of his evaluation, the patient
reported the new onset of vision changes, consisting of
intermittent, painless, blurred vision in both eyes. On
ophthalmologic examination, the best corrected visual
acuity was 20/20 in the right eye, and 20/30 in the left
eye. Vision acuity in the left eye was reduced from pre-
existing strabismic amblyopia. Examination of the ante-
rior segment was unremarkable, and intraocular pres-
sures were normal. Fundoscopic examination
demonstrated multiple, circumscribed, yellow-creamy
lesions of the choroids bilaterally (Figure 4). No vitritis
or retinal edema was present. A diagnosis of bilateral,
multifocal choroiditis was made and attributed to a rare
manifestation of intraocular BCG involvement [6].
Triple anti-mycobacterial therapy was initiated consist-
ing of rifampin (600 mg daily), isoniazid (300 mg daily),
and ethambutol (1200 mg daily) for a total of 12 months.
On treatment, the patient regained his prior weight, and
his physical exam and liver tests normalized (Figure 1).
On ophthalmologic examination, the previously noted
choroidal lesions had faded. The visual acuity remained
unchanged. A follow-up liver biopsy was performed after
the completion of anti-mycobacterial therapy. Scattered
Langerhans cells were still present, but repeat PCR test-
ing for Mycobacterium bovis was now negative.
Two months after the completion of anti-mycobacter-
ial therapy, the patient presented to our hospital with an
acute upper gastrointestinal hemorrhage. Emergency
endoscopy revealed an adherent clot in the third portion
of the duodenum. Abdominal CT examination revealed
Figure 2 Pathological features of liver biopsy of granulomatous hepatitis. Multiple non-caseating granulomas (A, ×10) and typical
Langerhans giant cells (B, ×40).
Figure 3 Bone marrow involvement with Mycobacterium bovis. Multiple non-caseating granulomas (arrows) with Langerhans giant cells (A.
×10). B. Higher magnification (×20).
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Compared to a study from one year prior, the diameter
of the aneurysm had increased from 2.8 cm in the prior
year to 4.1 cm and the aneurysm was impinging upon
the third portion of the duodenum (Figure 5). The
patient underwent emergency laparotomy, where an aor-
toduodenal fistualization with fresh clots was encoun-
tered. Aortic reconstruction and primary fistula repair
were performed successfully. The surgical specimen was
sent for pathologic and microbiological studies. Histolo-
gical examination revealed multifocal, non-caseating
granulomas with multinucleated giant cells (Figure 5).
Special stains for AFB and fungal organisms were nega-
tive. In light of the patient’s history of disseminated
BCG infection and the presence of multiple granulomas
on histological examination, it was felt that the patient
warranted retreatment for Mycobacterium bovis. He was
started on a repeat course of rifampin, isoniazid etham-
butol and pyridoxine/B6. The patient is tolerating his
treatment well and is currently asymptomatic.
The patient’s cultures and stains are all negative but
the pathology showed “multifocal, non-caseating small
granulomas with multinucleated foreign body giant cell
reaction and transmural chronic inflammation with mild
vascular congestion, clinically fistula”.
Conclusions
Bacillus Calmette-Guérin (BCG) is an attenuated strain
of the tuberculosis bacillus, Mycobacterium bovis.B C G
induces an intense, localized inflammatory response
upon instillation into the bladder. Its therapeutic
mechanism of action is thought to involve the ingestion
of viable mycobacteria by urothelial cells, which triggers
a cytokine-mediated inflammatory response that results
in the destruction of tumor cells.
Since its introduction in the 1970s, intravesical BCG
treatment has been an effective treatment option of
superficial bladder cancer, with a favorable safety profile
and typically localized and self-limited side effect [1].
However, systemic complications can occur. They
include granulomatous involvement of lung (pneumoni-
titis), liver (hepatitis), and bone marrow [4]. Ophthalmo-
logic and vascular complications have also been
described but are considered extremely rare.
According to our literature review, the combination of
granulomatous hepatitis, pneumonitis, choroiditis and
aorto-enteric fistulization due to disseminated Mycobac-
terium bovis infection has not previously been reported.
Our patient was initially referred for a hepatologic eva-
luation. His liver biopsy demonstrated the typical fea-
tures of granulomatous hepatitis with numerous
epitheloid noncaseating granulomas with intralobar dis-
tribution. Despite the negative acid fast stain, a high
level of suspicion for mycobacterial infection resulted in
further testing and the eventual establishment of multi-
organ involvement with Mycobacterium bovis BCG.
While hepatic, bone marrow, and pulmonary involve-
ment have been extensively documented, the occurrence
of mycobacterial choroiditis has only been reported in
one prior case report [6]. In this study, a 57 year-old
patient developed bilateral ocular lesions that resembled
those observed in our patient, following a 6-month
course with intravesical BCG with the Connaught strain.
Similar to our patient, his choroidal lesions did not pro-
gress after therapy with rifampin, isoniazid, and etham-
butol [6].
Figure 4 Ophthalmoscopic findings (multiple, circumscribed yellow-creamy lesions) of bilateral choroiditis with greater severity in the
left eye.
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due to disseminated BCG infection is a rare occurrence,
with less than 20 cases documented in the literature [8].
The proposed mechanisms of fistulization include hema-
togenous route via the vasa vasorum or local extension
and lymphatic spread [7,9].
Our case highlights the importance of considering
unusual complications of BCG therapy and of appropri-
ately monitoring patients at risk.
The proposed mechanisms of liver damage by BCG
include direct infection as well as hypersensitivity reac-
tions [10]. In 1996, Leebeek demonstrated the presence of
Mycobacterium bovis in liver tissues by PCR amplification
[11]. This finding supported the concept of hematogenous
dissemination and direct tissue damage to the liver
[11,12]. However, the beneficial effect of adding corticos-
teroids to the antituberculous agents and the striking eosi-
nophilic infiltration of the liver suggest that
hypersensitivity reactions may also play a role [12,13].
. The
absence of necrosis in the granulomas has been inter-
preted as additional evidence of a hypersensitivity reaction.
However, hepatic granuloma may resemble those seen in
miliary tuberculosis, in which necrosis is usually absent,
rather than the caseating lesions of primary tuberculosis
Figure 5 Duodenal pathology of aorto-duodenal fistula. A. (×4) single, small, non-caseating granuloma with multinucleated foreign body
giant cell reaction (arrow) and chronic transmural inflammation with vascular congestion, consistent with a fistula. L(lumen), m(mucosa), sm
(submucosa), mp(musularis propria). B. Close-up view of duodenal pathology. (×10) Non caseating granuloma with Langerhans giant cell (arrow).
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nosis, our case highlights the limitations of AFB staining
and conventional mycobacterial culture. Acid-fast stains
are positive in only 10 percent of cases with hepatic invol-
vement, possible due to the fact that a minimum of 10,000
organisms per gram of tissue are necessary to result in a
positive stain [12]. Mycobacterial cultures for the detection
of BCG lack sensitivity and require a minimum of six to
eight weeks of incubation. Molecular assays, including
PCR-based tests, have superior sensitivity. However, even
they may fail due to the paucity of organisms [12].
With respect to treatment, the recommended first line
therapy for severe systemic BCG infection is the administra-
tion of isoniazid, rifampin and ethambutol. Treatment with
pyrazinamide is not recommended since all known strains
of Mycobacterium bovis are pyrazinamide-resistant [10].
Adjunctive therapy with corticosteroids has been advocated
by some authors. This recommendation is based on data
from animal models and anecdotal clinical reports suggest-
ing that corticosteroids improve the histological outcomes
and treatment responses. However, corticosteroid should
not be given without concomitant antimycobacterial cover-
age since they might increase the risk of systemic infection.
With respect to prophylactic anti-mycobacterial treatment,
the concomitant administration of BCG and antitubercular
drugs has been advocated. However, this approach may
result in drug-induced hepatitis and reduce the antitumor
effects of BCG. Futhermore, systemic BCG infections can
occur despite antibiotic prophylaxis.
In summary, we present an unusual case of multi-organ
involvement with systemic mycobacterial infection fol-
lowing intravesical BCG treatment of bladder cancer in
an immunocompetent patient. The constellation of gran-
ulomatous hepatitis, choroiditis and aortoduodenal fistula
with gastrointestinal hemorrhage has not been previously
reported [3]. Our patient’s course highlights the impor-
tance of recognizing potential risks from BCG treatment
- even months after completion of treatment and in the
absence of a history of immunodeficiencies - and of
addressing its wide range of end-organ complications.
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